| Combination of | |
|---|---|
| Potassium citrate | Mineral supplement |
| Potassium hydrogen carbonate | Mineral supplement |
| Clinical data | |
| Trade names | Sibnayal |
| Other names | ADV7103, potassium citrate/potassium hydrogencarbonate, potassium citrate/potassium bicarbonate |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
Potassium citrate/potassium hydrogen carbonate, sold under the brand name Sibnayal, is a fixed-dose combination medication intended for the treatment of distal renal tubular acidosis.[1] It contains potassium citrate and potassium hydrogen carbonate.[1]
Potassium citrate/potassium hydrogen carbonate was approved for medical use in the European Union in April 2021.[1]
- ^ a b c d "Sibnayal EPAR". European Medicines Agency (EMA). 9 December 2020. Retrieved 22 May 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Sibnayal Product information". Union Register of medicinal products. Retrieved 3 March 2023.